TYK Medicines (Stock Code: 2410.HK) Successfully Listed on the Main Board of the Hong Kong Capital Market on August 20, 2024. The company publicly issued 47.88 million H shares in this offering, with 90% allocated for international placement and 10% for public offering. The issue price per share was HK$12.10, raising a total of HK$579 million.

In 2018, Boyuan Capital, as one of the earliest angel investment institutions, exclusively invested in the angel round financing of TYK Medicines.

Read the Original Text

Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. recently announced that it has received an increase in investment from the Shanghai Biomedical Industry Fund, with the investment amount reaching 1,197,530 RMB. The shareholding percentage increased from the original 3.8934% to 4.7089%, rising by 0.8155 percentage points.

Read the Original Text

Synthetic biology manufacturing company "MicroCyto" recently secured over 300 million RMB in its Series A round of financing, led by Beijing Capital Investment Fund. Participants in this round included Beijing Medical and Health Industry Fund, Shenzhen Capital Group, and Hebei Industrial Investment. Existing shareholders Guoguan Shunxi and Henan Investment Group's Huirong Fund continued to increase their investments.

Read the Original Text

Recently, the bipolar steerable sheath independently developed by Shanghai Huihe Healthcare Technology Co., Ltd. has been officially approved for marketing by the National Medical Products Administration (NMPA)!

Read the Original Text

On August 10, the "2024 Chinese Medical Doctor Association Urological Surgeons Branch (CUDA) Annual Conference," hosted by the Chinese Medical Doctor Association and the Urological Surgeons Branch of the Chinese Medical Doctor Association, grandly opened in Xi'an. At this grand event, the all-new generation Edge Medical multi-port endoscopic surgical robot MP2000 made its heavyweight debut — with seven major advancements, it reached a new height in overall performance, dazzling the entire audience.

Read the Original Text

Recently, the Free Testosterone Universal Calibrator and Quality Control Products developed and manufactured by Hangzhou Gloria Spectrum have officially been approved for a Class II Medical Device Registration Certificate. These products are mainly used for quantitative calibration and quality control in serum free testosterone testing (using Liquid Chromatography-Tandem Mass Spectrometry) in medical institutions. As the first domestically produced Class II medical device product based on equilibrium dialysis combined with LC-MS/MS detection, it further enriches Hangzhou Gloria Spectrum's clinical mass spectrometry overall solution system. It not only provides clinical mass spectrometry users with more options that meet practical needs but also plays a key role in promoting the standardization and compliance of LC-MS/MS technology in the field of precision diagnostics.

Read the Original Text

On August 6, BRATTEA, a China-based medical science and technology innovation enterprise, received approval from the National Medical Products Administration (NMPA) for its self-developed Netrod® StarBelt™ Mesh Renal Artery Radiofrequency Ablation System (including a disposable mesh renal artery radiofrequency ablation catheter and renal artery radiofrequency ablation generator) (NMPA Approval Nos. 20243011385 and 20243011387). The system is designed to assist in the treatment of patients with resistant hypertension and those intolerant to antihypertensive medications. This breakthrough RDN procedure will offer a new treatment option for patients with hypertension!

Read the Original Text

On August 14, 2024, the Prizvalve Transcatheter Aortic Valve System ("Prizvalve"), independently developed by Shanghai Newpace Medical Technology Co., Ltd., received approval from the National Medical Products Administration (NMPA) of China for market launch. As the first domestically produced balloon-expandable valve to be marketed in China, this product is suitable for patients diagnosed with symptomatic, calcified, severe degenerative native aortic valve stenosis who are considered unsuitable for conventional surgical valve replacement based on an assessment by a cardiac team using a scoring system.

Read the Original Text

Recently, two brain neurology blood test kits based on single-molecule analysis strategies developed by Yuce Biotech—Glial Fibrillary Acidic Protein Assay Kit and Neurofilament Light Chain Protein Assay Kit—have successfully obtained the Class II Medical Device Registration Certificate approved by the Jiangsu Provincial Medical Products Administration. This approval signifies that Yuce Biotech will continue to focus on brain neurology blood biomarkers, accelerating the market layout for early screening and diagnosis of Alzheimer's disease. It will take the lead in advancing the diagnostic development of biomarkers in China’s traumatic brain injury field, fully leveraging the ultra-high sensitivity advantages of the single-molecule immunoassay platform to expedite the clinical translation and application of related blood biomarkers in the neuroscience field.

Read the Original Text

On August 21, 2024, Abogen Biosciences published a paper titled "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system" in Nucleic Acids Research, reporting its self-developed efficient RNA circularization cis-splicing system (hereinafter referred to as the "Cis system"). The circular RNA (circRNA) prepared by this system can significantly prolong protein expression, reduce innate immune activation, and offers advantages such as flexibility in splice site design, demonstrating broad application potential.

Read the Original Text

Beijing time, August 26, 2024 — Dr. Zheng Wu, CEO of Shanghai Aikang Biomedical Technology Co., Ltd., delivered a keynote speech titled "Development of Next Generation Broadly Active IPF Drug AK3280" at the 8th IPF Summit held in Boston, USA, on August 22. Dr. Wu reported on the preclinical and clinical research progress of the new generation anti-fibrotic drug AK3280, particularly the Phase 2 randomized, double-blind, multicenter clinical study conducted in subjects with idiopathic pulmonary fibrosis (IPF). He also announced that this study has completed the enrollment of all subjects. The study, led by Professor Huaping Dai from China-Japan Friendship Hospital, is being conducted across 31 hospitals in China to evaluate the safety, tolerability, and efficacy of AK3280 in subjects with idiopathic pulmonary fibrosis.

Read the Original Text

August 19, 2024 – CANbridge Pharmaceuticals Inc. (stock code “1228.HK”), a leading global biopharmaceutical company in China focused on the rare disease space, is committed to the research, development, and commercialization of innovative therapies. The company today announced positive topline results from the pivotal clinical trial of CAN103 in treatment-naïve subjects aged 12 years and older with Type I and Type III Gaucher disease.

Read the Original Text

Recently, Shanton Pharma announced that the Phase 2b clinical trial of its innovative therapy SAP-001 for treating refractory/tophaceous gout patients has completed full enrollment. This therapy is expected to provide a new solution for patients with refractory gout.

Read the Original Text

The six clinical trial applications for ZT006 tablets, a Class 1 new drug submitted by Beijing Zhip肽 Biopharmaceutical Technology Co., Ltd., were accepted and disclosed on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration on August 27, 2024.

Read the Original Text